These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 35112773)

  • 1. Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.
    Nguy J; Hitchen SA; Lan NSR; Dwivedi G; Larbalestier R; Yeap BB; Fegan PG
    Intern Med J; 2023 Jun; 53(6):994-1001. PubMed ID: 35112773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
    Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F
    Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
    Hao Y; Yang YL; Wang YC; Li J
    Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
    Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
    Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
    Schwartz GG; Giugliano RP
    Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center.
    Tsai CL; Chang YH; Su CH; Wu YJ; Yeh HI; Lin CF
    J Formos Med Assoc; 2022 Sep; 121(9):1877-1880. PubMed ID: 34852937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice.
    Bradley CK; Kolkailah AA; Shah NP; Page CB; Peterson ED; Navar AM
    J Clin Lipidol; 2023; 17(3):412-414. PubMed ID: 37029056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
    Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
    Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
    Paraskevas KI; Gloviczki P; Antignani PL; Comerota AJ; Dardik A; Davies AH; Eckstein HH; Faggioli G; Fernandes E Fernandes J; Fraedrich G; Geroulakos G; Golledge J; Gupta A; Gurevich VS; Jawien A; Jezovnik MK; Kakkos SK; Knoflach M; Lanza G; Liapis CD; Loftus IM; Mansilha A; Nicolaides AN; Pini R; Poredos P; Proczka RM; Ricco JB; Rundek T; Saba L; Schlachetzki F; Silvestrini M; Spinelli F; Stilo F; Suri JS; Svetlikov AV; Zeebregts CJ; Chaturvedi S; Veith FJ; Mikhailidis DP
    Prog Cardiovasc Dis; 2022; 73():41-47. PubMed ID: 35605696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LIpid Response to Statins ± Ezetimibe In Mumbai (LIRIM): A Cross-sectional Observational Study.
    Shah VT
    J Assoc Physicians India; 2024 Sep; 72(9):64-72. PubMed ID: 39291519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
    Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
    J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
    Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
    Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.